A Major Unmet Need in a Rapidly Growing Market
The global female infertility market exceeds USD 39 billion and is projected to grow beyond USD 85 billion by 2034.
IVF success rates remain capped at ~35%.
Embryo selection has largely been optimized.
The uterine environment is now the limiting factor.
Impaired lymphatic function in the endometrium prevents stable implantation — and is not addressed by current IVF add-ons.
Restoring implantation capacity, not just optimizing embryos
Vessely™ is a prescription-based, locally administered lymphangiogenic therapy designed for use within IVF clinics. It targets the uterine microenvironment to restore endometrial readiness for implantation.
Clinic-Ready Therapy
Designed for integration into existing IVF workflows without disrupting standard protocols.
Non-Hormonal Approach
Acts locally on the endometrium without systemic hormonal intervention.
Microenvironment-Focused
Addresses lymphatic dysfunction within the uterine tissue — not embryo selection.
Vessely™ restores the endometrium itself — a fundamentally different approach to improving IVF outcomes.
Unlocking the Endometrium’s Lymphatic Network
Vessely™ is designed to restore the lymphatic system within the endometrium — a critical regulator of immune balance, fluid homeostasis, and tissue stability during implantation. By regenerating functional lymphatic vessels, Vessely™ helps re-establish a uterine environment capable of supporting stable embryo attachment and early pregnancy.
Robust and Reproducible Restoration of Implantation
Vessely™ has demonstrated consistent restoration of implantation in a severe infertility model, providing direct evidence of lymphatic regeneration as a causal driver of fertility outcomes.
Severe Infertility Model (IUA)
Validated large-animal model representing profound implantation failure.
One-Sided Infertility
Implantation restored exclusively in treated uterine tissue, demonstrating localized biological effect.
Reproducibility
Consistent outcomes observed across multiple animals and study repeats.
Demonstrates biological causality — not correlation.
A Direct Translational Bridge to Human Infertility
Cows serve as a translational engine rather than the end market. Their uterine size and physiology provide a human-relevant model that allows us to optimize dosing, refine manufacturing processes, and design clinical trials with confidence. This ethical, non-lethal approach ensures that preclinical studies are both scientifically rigorous and humane, while generating data that is directly applicable to human infertility. By bridging large-animal studies to First-in-Human trials, Vessely™ de-risks the path to clinical development and demonstrates the therapy’s potential in a real-world IVF setting.
Science & Platform
This is where investors see the depth, legitimacy, and future potential of your technology. It’s credibility-heavy but should remain readable, paragraph-style, and confidence-building.
✦ Show 15+ years of R&D
✦ Highlight platform capabilities
✦ Showcase patents & publications at a high level
✦ Introduce future pipeline opportunities without diluting focus
Science Overview:
For over 15 years, LYMPHOGENiX has pioneered research into lymphangiogenesis, uncovering the critical role of lymphatic vessels in supporting implantation and tissue regeneration. Our discoveries are backed by multiple peer-reviewed publications and a portfolio of proprietary patents, providing a strong foundation for both human and veterinary applications.
Platform & Pipeline:
At the core of LYMPHOGENiX is a robust regenerative platform capable of developing therapies across multiple indications. While infertility remains our primary focus, our technology holds potential in areas such as fibrosis, skin aging, and metabolic disorders. Each opportunity is approached with discipline, ensuring that current focus is never diluted while positioning the company for future growth.
Invest in LYMPHOGENiX
LYMPHOGENiX is raising $5M to advance Vessely™ through preclinical development, CMC optimization, and regulatory preparation for First-in-Human trials. These funds will accelerate our path toward clinical translation, ensuring readiness for a successful human study in 2027.
Over the next two years, we will complete GLP studies, finalize manufacturing processes, and prepare regulatory submissions. This disciplined approach de-risks the transition from preclinical research to clinical application.
Our strategy is focused on strategic licensing or acquisition by a leading IVF pharmaceutical company, offering investors a clear and attainable path to value realization.
15+ years R&D ✦ 6 international patents ✦ Large-animal PoC completed ✦ First-in-Human planned (2027) ✦
